### Medtronic Diabetes: Leading the Way in Insulin Pump Technology Medtronic Diabetes has been a pioneer in diabetes technology, especially in the field of insulin pumps. They have a long history of innovation, starting with the Minimed 670G, the first hybrid closed-loop system approved by the FDA in 2016. This system partially automates insulin delivery, adjusting basal insulin every 5 minutes based on continuous glucose monitor (CGM) readings. However, users still need to input carb counts and bolus amounts for meals. In 2020, Medtronic acquired Companion Medical, the maker of the InPen, a smart insulin pen that connects with an app to provide personalized dosing recommendations. This acquisition allows Medtronic to offer an alternative to insulin pumps for those who prefer injections. Medtronic's Guardian Connect is a stand-alone CGM device that has been available since 2018. It offers data-sharing capabilities via Bluetooth and does not require a dedicated receiver. The company is also working on next-generation CGM sensors and a new 7-day infusion set that can be worn twice as long as current sets. Looking ahead, Medtronic is developing the 780G Advanced Hybrid Closed Loop system, which aims to offer more customized control via a smartphone interface. This system is expected to improve time-in-range (TIR) outcomes and user satisfaction. Medtronic is also focusing on making their devices more interoperable with other diabetes technologies, such as Dexcom's CGM. Despite some controversies, such as their exclusive deal with United Health Care, Medtronic continues to be a leader in diabetes technology, pushing the boundaries of what's possible to improve the lives of people with diabetes.